Payment overview · 2025
General Payments
$276.58
14 reported records · 8 companies
Healthcare provider profile · identity verified
Erika Leung, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STE GENEVIEVE, MO · NPI 1326453721
Verified facts
What the public records show
CMS Open Payments records show Erika Leung, M.D. received $276.58 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 493 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.62 | 20.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.85 | 20.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 13.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.32 | 13.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.50 | 10.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.98 | 8.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.72 | 7.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.05 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.04 | 13 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.54 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.32 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
493 | 42 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 913 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 679 | 81 |
| Eliquis | Apixaban | 493 | 42 |
| Lisinopril | Lisinopril | 473 | 83 |
| Furosemide | Furosemide | 449 | 63 |
| Potassium Chloride | Potassium Chloride | 412 | 73 |
| Metformin Hcl | Metformin Hcl | 404 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 77 |
| Omeprazole | Omeprazole | 360 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 347 | 57 |
| Sertraline Hcl | Sertraline Hcl | 323 | 51 |
| Losartan Potassium | Losartan Potassium | 299 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 296 | 48 |
| Gabapentin | Gabapentin | 266 | 48 |
| Simvastatin | Simvastatin | 247 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 232 | 37 |
| Trazodone Hcl | Trazodone Hcl | 230 | 44 |
| Montelukast Sodium | Montelukast Sodium | 227 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 224 | 34 |
| Allopurinol | Allopurinol | 221 | 25 |
| Mirtazapine | Mirtazapine | 213 | 28 |
| Carvedilol | Carvedilol | 192 | 28 |
| Famotidine | Famotidine | 189 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 47 |
| Donepezil Hcl | Donepezil Hcl | 180 | 29 |
| Jardiance | Empagliflozin | 170 | 27 |
| Prednisone | Prednisone | 170 | 98 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 19 |
| Farxiga | Dapagliflozin Propanediol | 159 | 16 |
| Spironolactone | Spironolactone | 154 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 34 |
| Alprazolam | Alprazolam | 145 | 30 |
| Lorazepam | Lorazepam | 144 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 139 | 23 |
| Risperidone | Risperidone | 125 | 11 |
| Finasteride | Finasteride | 124 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 30 |
| Memantine Hcl | Memantine Hcl | 121 | 19 |
| Bumetanide | Bumetanide | 117 | 16 |
| Tramadol Hcl | Tramadol Hcl | 115 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 23 |
| Meloxicam | Meloxicam | 104 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 28 |
| Levetiracetam | Levetiracetam | 99 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 18 |
| Alendronate Sodium | Alendronate Sodium | 94 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 14 |
| Torsemide | Torsemide | 91 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 16 |
| Myrbetriq | Mirabegron | 89 | suppressed |
| Glipizide | Glipizide | 88 | 23 |
| Atenolol | Atenolol | 85 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | suppressed |
| Ezetimibe | Ezetimibe | 78 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 27 |
| Divalproex Sodium | Divalproex Sodium | 73 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 72 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 23 |
| Entresto | Sacubitril/Valsartan | 67 | suppressed |
| Baclofen | Baclofen | 66 | 11 |
| Lovastatin | Lovastatin | 59 | suppressed |
| Topiramate | Topiramate | 55 | suppressed |
| Ozempic | Semaglutide | 54 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 40 |
| Metformin Hcl Er | Metformin Hcl | 53 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 12 |
| Olanzapine | Olanzapine | 50 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 14 |
| Austedo | Deutetrabenazine | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 14 |
| Temazepam | Temazepam | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 26 |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 27 | suppressed |
| Cartia Xt | Diltiazem Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 17 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | 15 |
| Dorzolamide Hcl | Dorzolamide Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Acetic Acid | Acetic Acid | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Linzess | Linaclotide | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Perseris | Risperidone | 13 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 12 | suppressed |
| Nystop | Nystatin | 12 | 11 |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $276.58 · 14 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, GEMTESA, LEQVIO, NURTEC ODT, Ozempic, PREVNAR 20, REPATHA, REXULTI, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error